Vext Science Inc (VV5) - Net Assets
Based on the latest financial reports, Vext Science Inc (VV5) has net assets worth €71.04 Million EUR (≈ $83.05 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€132.88 Million ≈ $155.36 Million USD) and total liabilities (€61.84 Million ≈ $72.30 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VV5 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €71.04 Million |
| % of Total Assets | 53.46% |
| Annual Growth Rate | 36.05% |
| 5-Year Change | 108.56% |
| 10-Year Change | N/A |
| Growth Volatility | 32.99 |
Vext Science Inc - Net Assets Trend (2017–2024)
This chart illustrates how Vext Science Inc's net assets have evolved over time, based on quarterly financial data. Also explore VV5 asset base for the complete picture of this company's asset base.
Annual Net Assets for Vext Science Inc (2017–2024)
The table below shows the annual net assets of Vext Science Inc from 2017 to 2024. For live valuation and market cap data, see Vext Science Inc (VV5) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €75.74 Million ≈ $88.54 Million |
-20.26% |
| 2023-12-31 | €94.98 Million ≈ $111.04 Million |
+32.07% |
| 2022-12-31 | €71.92 Million ≈ $84.08 Million |
+21.09% |
| 2021-12-31 | €59.39 Million ≈ $69.44 Million |
+63.56% |
| 2020-12-31 | €36.31 Million ≈ $42.45 Million |
+41.44% |
| 2019-12-31 | €25.67 Million ≈ $30.01 Million |
+51.01% |
| 2018-12-31 | €17.00 Million ≈ $19.88 Million |
+93.75% |
| 2017-12-31 | €8.77 Million ≈ $10.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Vext Science Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 74.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €15.29 Million | 20.18% |
| Other Components | €60.45 Million | 79.82% |
| Total Equity | €75.74 Million | 100.00% |
Vext Science Inc Competitors by Market Cap
The table below lists competitors of Vext Science Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eternal Energy Public Company Limited
BK:EE
|
$36.39 Million |
|
AViTA Corporation
TWO:4735
|
$36.39 Million |
|
EuroDry Ltd
NASDAQ:EDRY
|
$36.41 Million |
|
Sangsin Brake
KO:041650
|
$36.41 Million |
|
Star Equity Holdings Inc
NASDAQ:STRR
|
$36.37 Million |
|
Dividend Select 15 Corp
TO:DS
|
$36.33 Million |
|
Relief Therapeutics Holding AG
SW:RLF
|
$36.33 Million |
|
Doctor Care Anywhere Group Plc
AU:DOC
|
$36.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vext Science Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 94,982,275 to 75,735,677, a change of -19,246,598 (-20.3%).
- Net loss of 22,435,176 reduced equity.
- Other factors increased equity by 3,188,578.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-22.44 Million | -29.62% |
| Other Changes | €3.19 Million | +4.21% |
| Total Change | €- | -20.26% |
Book Value vs Market Value Analysis
This analysis compares Vext Science Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.67x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.43x to 0.67x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.47 | €0.20 | x |
| 2018-12-31 | €0.91 | €0.20 | x |
| 2019-12-31 | €1.14 | €0.20 | x |
| 2020-12-31 | €0.77 | €0.20 | x |
| 2021-12-31 | €0.84 | €0.20 | x |
| 2022-12-31 | €0.87 | €0.20 | x |
| 2023-12-31 | €0.63 | €0.20 | x |
| 2024-12-31 | €0.31 | €0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vext Science Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -62.32%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.81x
- Recent ROE (-29.62%) is below the historical average (10.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 46.81% | 27.66% | 1.07x | 1.58x | €3.23 Million |
| 2018 | 22.05% | 20.29% | 0.79x | 1.38x | €2.05 Million |
| 2019 | 10.88% | 12.51% | 0.58x | 1.51x | €226.00K |
| 2020 | 5.85% | 8.43% | 0.45x | 1.53x | €-1.51 Million |
| 2021 | 8.40% | 13.39% | 0.44x | 1.41x | €-952.64K |
| 2022 | 15.18% | 30.84% | 0.29x | 1.68x | €3.73 Million |
| 2023 | 4.63% | 12.63% | 0.23x | 1.57x | €-5.10 Million |
| 2024 | -29.62% | -62.32% | 0.26x | 1.81x | €-30.01 Million |
Industry Comparison
This section compares Vext Science Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $796,231,369
- Average return on equity (ROE) among peers: -46.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vext Science Inc (VV5) | €71.04 Million | 46.81% | 0.87x | $36.39 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $6.65 Billion | 14.85% | 0.54x | $692.11 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $2.69 Million | -197.11% | 3.73x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-815.79K | 0.00% | 0.00x | $134.78K |
| EQL PHARMA AB (7JK) | $154.75 Million | 19.98% | 0.85x | $148.83 Million |
| Alkermes plc (8AK) | $1.11 Billion | -4.33% | 0.82x | $5.00 Billion |
| OPTIMI HEALTH CORP. (8BN) | $16.02 Million | -45.89% | 0.05x | $17.99 Million |
| LABIANA HEALTH S.A.EO-10 (8RK) | $3.40 Million | -129.96% | 16.37x | $40.60 Million |
| CANNABIS POLAND AB ZY-10 (8TE) | $1.36 Million | -85.24% | 0.35x | $1.75 Million |
| Apontis Pharma AG (APPH) | $30.26 Million | -37.35% | 0.90x | $91.63 Million |
| CRAFTPORT CANNABIS CORP. (BBW0) | $-3.18 Million | 0.00% | 0.00x | $1.45 Million |
About Vext Science Inc
Vext Science, Inc., through its subsidiaries, provides integrated agricultural technology, services, and property management services in the cannabis industry in the United States. It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles. The company al… Read more